证券代码：600694 证券简称：大商股份 编号：2025－013 大商股份有限公司 2025年限制性股票激励计划授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 大商股份有限公司（以下简称"公司"）第十一届董事会第二十七次会议和2025年第一次临时股东大会， 审议通过了《关于〈公司2025年限制性股票激励计划（草案）〉及其摘要的议案》。根据《上市公司股 权激励管理办法》的规定，公司按照上海证券交易所、中国证券登记结算有限责任公司上海分公司有关 要求完成了公司2025年限制性股票激励计划（以下简称"本次激励计划"、"本激励计划"）限制性股票授 予登记工作，有关具体情况公告如下： 一、限制性股票授予的具体情况 公司于2025年3月20日召开第十一届董事会第二十八次、第十一届监事会第十八次会议，均审议通过了 《关于向公司2025年限制性股票激励计划激励对象授予限制性股票的议案》。同意以2025年3月20日作 为本激励计划的授予日，授予价格13.03元/股，向激励对象授予310.00万股限制性股票。 公司 ...

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. plans to repurchase and cancel 14,000 restricted stocks due to the departure of one incentive object from the 2024 Restricted Stock Incentive Plan [2][4][10] Summary by Sections Repurchase and Cancellation Reasons - The repurchase and cancellation of restricted stocks is based on the "Management Measures for Equity Incentives of Listed Companies" and the company's 2024 Restricted Stock Incentive Plan, as one incentive object has left the company [2][4] Details of the Repurchase and Cancellation - The decision for the repurchase was approved in meetings held on February 12, 2025, and the company has completed the necessary creditor notification procedures [3][4] - The repurchase involves one incentive object and a total of 14,000 restricted stocks, leaving 2,156,103 restricted stocks remaining after the cancellation [6][10] Repurchase Arrangement - The company has opened a dedicated securities account for the repurchase and expects to complete the cancellation by April 14, 2025 [6][10] Impact on Share Structure - After the cancellation, the company's share structure will be adjusted, but the specific changes will be confirmed by the China Securities Depository and Clearing Corporation [6][10] Legal Compliance and Commitments - The board of directors confirms that the decision-making process and information disclosure comply with relevant laws and regulations, ensuring no harm to the rights of the incentive objects or creditors [7][10] Convertible Bond Information - The repurchase of restricted stocks does not affect the conversion price of the company's convertible bonds, which remains at 20.28 yuan per share [10][16] - The company issued 6.9 million convertible bonds in 2023, with a total amount of 69 million yuan, and the bonds are currently trading on the Shanghai Stock Exchange [10][11]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603153 证券简称：上海建科 公告编号：2025-013 特此公告。 上海建科咨询集团股份有限公司董事会 2025年4月9日 上海建科咨询集团股份有限公司 关于选举职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 上海建科咨询集团股份有限公司（以下简称"公司"）于2025年4月7日召开八届十次职工代表大会，选举 王昊先生（简历附后）为公司董事会职工董事。 王昊先生将与公司股东会选举产生的新一届董事会成员共同组成公司第二届董事会，任期与第二届董事 会一致。 上海建科咨询集团股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购审批情况和回购方案内容 附：王昊先生简历 王昊，男，汉族，1971年3月出生，大学学历，管理学硕士，正高级工程师。曾任上海投资咨询公司产 业科技部主任、市场发展部主任、副总经 ...

Core Viewpoint - The company plans to repurchase its shares with a total fund not exceeding RMB 100 million and not less than RMB 50 million, aiming to enhance employee motivation and investor confidence through stock incentive plans [1][4][11]. Summary by Sections Repurchase Plan Overview - The repurchase will utilize the company's own funds and a special loan from CITIC Bank, not exceeding RMB 90 million [1][13]. - The maximum repurchase price is set at RMB 32.00 per share, which is 150% of the average trading price over the previous 30 trading days [1][12]. - The repurchase will be conducted through centralized bidding and is expected to be completed within 12 months from the board's approval [1][8]. Purpose and Use of Repurchased Shares - The shares repurchased will be used for employee stock ownership plans and/or equity incentives, with a requirement to utilize them within three years [5][11]. - If not utilized within the specified period, the company will proceed with capital reduction procedures to cancel the unutilized shares [5][17]. Financial Impact and Structure Changes - The repurchase is projected to account for approximately 0.39% to 0.78% of the company's total share capital, depending on the total amount spent [11][14]. - The total repurchase amount, if at the upper limit, will represent 4.83% of total assets, 5.67% of net assets, and 8.03% of current assets, indicating a low impact on the company's financial health [15]. Compliance and Governance - The repurchase plan was proposed by the controlling shareholder and approved by the board without the need for a shareholder meeting [4][16]. - There are no current plans for share reduction by major shareholders or executives in the next three to six months [1][11]. Authorization and Implementation - The board has authorized management to execute the repurchase plan, including setting up a dedicated securities account for the repurchase [19][22]. - The company will adjust the repurchase plan in response to any changes in regulations or market conditions [19][20].

Core Viewpoint - Jiangsu Jibeier Pharmaceutical Co., Ltd. has announced the approval and public disclosure of the list of incentive recipients for its 2025 restricted stock incentive plan, ensuring compliance with relevant regulations and internal governance [1][2]. Disclosure Situation - The company disclosed the draft of the 2025 restricted stock incentive plan and its summary on the Shanghai Stock Exchange website on March 29, 2025 [1]. - From March 29 to April 7, 2025, the names and positions of the first batch of incentive recipients were publicly announced internally for a period of 10 days, during which no objections were raised [2]. Verification Opinions - The supervisory board confirmed that the recipients of the incentive plan meet the conditions set forth in the relevant laws, regulations, and the draft plan, excluding supervisors and independent directors from the list [2]. - The recipients possess the necessary qualifications as per the Company Law and the company's articles of association, and do not fall under any disqualifying conditions outlined in the management regulations [2].

Investment Rating - The investment rating for the company is "Outperform the Market" [6][18]. Core Viewpoints - The company is facing short-term operational pressure, with a projected revenue of 14.063 billion yuan in 2024, a decrease of 4.00%, and a net profit of 911 million yuan, down 9.06% [10][18]. - The company has exceeded its store opening target for 2024, opening 1,515 new stores and closing 519, resulting in a net increase of 968 stores, maintaining its position as the largest domestic hotel chain [2][14]. - The company plans to open 1,300 new stores and sign 2,000 contracts in 2025, with expected revenue growth of 2%-7% [4][17]. Summary by Sections Financial Performance - In 2024, the company reported a revenue of 14.063 billion yuan, a decline of 4.00%, and a net profit of 911 million yuan, down 9.06% [10][18]. - The fourth quarter of 2024 saw a revenue of 3.273 billion yuan, a decrease of 8.51%, with a net loss of 195 million yuan [10][18]. - The company achieved a cumulative dividend payout ratio of 58.54% for the year, an increase of 5.13 percentage points year-on-year [10][18]. Operational Highlights - The company’s domestic limited-service hotel segment experienced a RevPAR decline of 5.78% in 2024, with the fourth quarter showing a reduced decline of 4.93% compared to the previous quarter [2][14]. - The company’s overseas hotel segment reported a revenue of 4.289 billion yuan, a decrease of 1.0%, with net losses increasing to 437 million yuan [3][16]. Future Outlook - The company is in a gradual integration phase, with expectations for improved performance driven by policy support and operational enhancements [4][17]. - The company aims to achieve a non-GAAP net profit of no less than 12.77 billion yuan in 2025, contingent on industry recovery and internal integration efforts [4][17]. - The company’s financial pressure is expected to ease with anticipated reductions in financial costs due to capital restructuring and interest rate cuts [4][17].

Group 1 - Southbound funds significantly net bought 28.79 billion HKD in Hong Kong stocks on April 3, marking the second-highest single-day net purchase in history, following 29.63 billion HKD on March 10, 2025 [1] - The net purchases included 16.99 billion HKD from the Shanghai-Hong Kong Stock Connect and 11.80 billion HKD from the Shenzhen-Hong Kong Stock Connect, indicating strong investor confidence in the market [1] Group 2 - Zai Ding Pharmaceutical announced the grant of stock options and restricted stock units totaling 65.78 thousand shares of American Depositary Shares to 40 and 381 recipients respectively, reflecting the company's confidence in future growth [2] - The stock incentive plan aims to attract and retain talent, which could positively impact the company's performance [2] Group 3 - Huolala submitted its fifth listing application to the Hong Kong Stock Exchange, reporting a revenue of 1.593 billion USD for the previous year, a year-on-year increase of 19.39% [3] - The listing application is backed by major investors including Hillhouse Capital and Sequoia China, indicating strong market interest [3] Group 4 - Chifeng Jilong Gold Mining exercised its overallotment option, issuing 30.84 million H-shares at a price of 13.72 HKD per share, increasing the total issued shares from 205.7 million to 236.5 million [4] - This move demonstrates the company's financing capability and market demand [4] Group 5 - Zhao Wei Electromechanical plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange, indicating the company's intention to expand into international markets [5] - The company will consider the interests of existing shareholders and market conditions when determining the timing of the issuance [5]

的获益条件 归属日 指 须为交易日 《公司法》 指 《中华人民共和国公司法》 《证券法》 指 《中华人民共和国证券法》 《管理办法》 指 《上市公司股权激励管理办法》 《上市规则》 指 《深圳证券交易所创业板股票上市规则》 《深圳证券交易所创业板上市公司自律监管指南第 1 号— 《自律监管指南》 指 —业务办理》 《公司章程》 指 《昆仑万维科技股份有限公司章程》 因《公司法》《管理办法》及相关的法律法规修订，公司 治理结构比照前述法规进行调整之后，未来将由公司董事 监督机构 指 会薪酬与考核委员会或审计委员会等法定机构承继公司监 事会 薪酬委员会 公司董事会薪酬与考核委员会 中国证监会 指 中国证券监督管理委员会 证券交易所 指 深圳证券交易所 登记结算公司 指 中国证券登记结算有限责任公司深圳分公司 元、万元 指 中华人民共和国法定货币人民币元、万元 正 文 一、公司实施本激励计划的主体资格 （一）公司基本情况 公司成立于 2008 年 03 月 27 日。2015 年 01 月 04 日，公司经中国证监会发 文《关于核准北京昆仑万维科技股份有限公司首次公开发行股票的批复》（证监 许可201516 号）， ...

证券代码：300418 证券简称：昆仑万维 公告编号：2025-010 昆仑万维科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别声明 券法》第九十条、《上市公司股东大会规则》第三十一条以及《公开征集上市公司股东 权利管理暂行规定》第三条规定的征集条件。 根据中国证券监督管理委员会（以下简称 "证监会"）《上市公司股权激励管理 办法》（以下简称"《管理办法》"）的有关规定，昆仑万维科技股份有限公司（以下 简称"公司"）独立董事张晨宇受其他独立董事的委托作为征集人，就公司拟于 2025 年 4 月 21 日召开的 2025 年第一次临时股东大会审议的相关议案向公司全体股东征集投 票权。 证监会、深圳证券交易所及其他政府部门未对本报告书所述内容之真实性、准确性 和完整性发表任何意见，对本报告书的内容不负有任何责任，任何与之相反的声明均属 虚假不实陈述。 一、征集人基本情况 张晨宇，男，1989年7月出生，中国国籍，无永久境外居留权，对外经济贸易大学 会计学专业毕业，博士学位。现任北京工商大学会计系主任。2023年7月起任公司独立 董事。 法行为 ...

次授予激励对象具备《公司法》《证券法》《上市规则》等法律、法规和规范性文 件及《公司章程》规定的任职资格，且不存在下列情形：（1）最近12个月内被证 券交易所认定为不适当人选；（2）最近12个月内被中国证监会及其派出机构认定 为不适当人选；（3）最近12个月内因重大违法违规行为被中国证监会及其派出机 构行政处罚或者采取市场禁入措施；（4）具有《公司法》规定的不得担任公司董 事、高级管理人员情形的；（5）法律法规规定不得参与上市公司股权激励的；（6） 中国证监会认定的其他情形。本激励计划涉及的首次授予激励对象未包括公司的独 立董事、监事以及外籍员工。本激励计划涉及的首次授予激励对象均符合《管理办 法》《上市规则》规定的激励对象条件，符合《激励计划（草案）》规定的激励对 象范围，其作为本激励计划激励对象的主体资格合法、有效。公司将在召开股东大 会前，通过公司网站或其他途径，在公司内部公示激励对象的姓名和职务，公示期 不少于10天。监事会将于股东大会审议股权激励前5日披露对激励对象名单的审核 意见及其公示情况的说明。 杭州安恒信息技术股份有限公司监事会 关于《公司2025年限制性股票激励计划（草案）》的核查意见 杭 ...